{"protocolSection":{"identificationModule":{"nctId":"NCT04405076","orgStudyIdInfo":{"id":"mRNA-1273-P201"},"secondaryIdInfos":[{"id":"75A50120C00034","type":"OTHER_GRANT","domain":"BARDA"}],"organization":{"fullName":"ModernaTX, Inc.","class":"INDUSTRY"},"briefTitle":"Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older","officialTitle":"A Phase 2a, Randomized, Observer-Blind, Placebo Controlled, Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 SARS-COV-2 Vaccine in Adults Aged 18 Years and Older"},"statusModule":{"statusVerifiedDate":"2022-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2020-05-29","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2021-10-28","type":"ACTUAL"},"completionDateStruct":{"date":"2021-10-28","type":"ACTUAL"},"studyFirstSubmitDate":"2020-05-13","studyFirstSubmitQcDate":"2020-05-26","studyFirstPostDateStruct":{"date":"2020-05-28","type":"ACTUAL"},"resultsFirstSubmitDate":"2022-10-21","resultsFirstSubmitQcDate":"2022-12-06","resultsFirstPostDateStruct":{"date":"2022-12-30","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-12-06","lastUpdatePostDateStruct":{"date":"2022-12-30","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"ModernaTX, Inc.","class":"INDUSTRY"},"collaborators":[{"name":"Biomedical Advanced Research and Development Authority","class":"FED"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This clinical study will assess the safety, reactogenicity, and immunogenicity of 2 dose levels of mRNA-1273 Severe Acute Respiratory Syndrome coronavirus (SARS-COV-2) vaccine in adults 18 years of age or older.","detailedDescription":"This is a 3-part Phase 2a study, with Part A (Blinded Phase), Part B (Open-label Interventional Phase), and Part C (Rollover Proof of Concept).\n\nParticipants in Part A are blinded to their treatment assignment, with participants receiving either 2 active mRNA-1273 vaccine doses or placebo. Part B of the study is designed to offer participants to be unblinded so that participants who received placebo in Part A can request 2 doses of open-label mRNA-1273 vaccine. Additionally, participants who originally received 1 or 2 doses of mRNA-1273 (50 microgram \\[μg\\] or 100 μg vaccine) during Part A, will have the opportunity to request to receive a single booster dose of mRNA-1273.\n\nPart C will be a proof-of-concept rollover study to evaluate a vaccine to treat mutations of SARS-CoV2, such as the S-protein of the B.1.351 variant. Part C will include approximately 60 participants, who are currently enrolled in Moderna's Phase 3 mRNA-1273-P301 study (NCT04470427), have already been unblinded, and have previously received 2 doses of mRNA-1273 at least 6 months earlier. At enrollment into Part C of this study, their participation in mRNA-1273-P301 study will be terminated. Part C will evaluate the safety and immunogenicity of 2 dose levels (20 µg and 50 µg) of mRNA-1273.351 and mRNA-1273/mRNA-1273.351 mixture (50 µg total), given as a single booster dose."},"conditionsModule":{"conditions":["SARS-CoV-2"],"keywords":["mRNA-1273","mRNA-1273 vaccine","mRNA-1273.351","SARS-CoV-2","SARS-CoV-2 Vaccine","Coronavirus","Virus Diseases","Messenger RNA","COVID 19","COVID 19 Vaccine","Moderna"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"DOUBLE","maskingDescription":"Part A is observer-blind. During Part B participants may request to be unblinded by scheduling a Participant Decision clinic visit. Part C is open-label.","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":660,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"mRNA-1273: Dose 50 microgram (ug) - Participants Aged 18-54 years","type":"EXPERIMENTAL","description":"Part A: Participants aged 18-54 years will receive 1 intramuscular (IM) injection of 50 ug mRNA-1273 on Day 1 and on Day 29.\n\nPart B: Participants aged 18-54 years who choose to be unblinded and received 50 ug mRNA-1273 during Part A, will receive 1 IM injection of mRNA-1273 (booster dose) on Day 1.","interventionNames":["Biological: Biological: mRNA-1273"]},{"label":"mRNA-1273: Dose 50 ug - Participants Aged 55+ years","type":"EXPERIMENTAL","description":"Part A: Participants aged 55+ years will receive 1 IM injection of 50 ug mRNA-1273 on Day 1 and on Day 29.\n\nPart B: Participants aged 55+ years who choose to be unblinded and received 50 ug mRNA-1273 during Part A, will receive 1 IM injection of mRNA-1273 (booster dose) on Day 1.","interventionNames":["Biological: Biological: mRNA-1273"]},{"label":"mRNA-1273: Dose 100 ug - Participants Aged 18-54 years","type":"EXPERIMENTAL","description":"Part A: Participants aged 18-54 years will receive 1 IM injection of 100 ug mRNA-1273 on Day 1 and on Day 29.\n\nPart B: Participants aged 18-54 years who choose to be unblinded and received 100 ug mRNA-1273 during Part A, will receive 1 IM injection of mRNA-1273 (booster dose) on Day 1.","interventionNames":["Biological: Biological: mRNA-1273"]},{"label":"mRNA-1273: Dose 100 ug - Participants Aged 55+ years","type":"EXPERIMENTAL","description":"Part A: Participants aged 55+ years will receive 1 IM injection of 100 ug mRNA-1273 on Day 1 and on Day 29.\n\nPart B: Participants aged 55+ years who choose to be unblinded and received 100 ug mRNA-1273 during Part A, will receive 1 IM injection of mRNA-1273 (booster dose) on Day 1.","interventionNames":["Biological: Biological: mRNA-1273"]},{"label":"Placebo (Part A) and mRNA-1273 100 ug (Part B) - Participants Aged 18-54 years","type":"PLACEBO_COMPARATOR","description":"Part A: Participants aged 18-54 years will receive 1 IM injection of mRNA-1273-matching placebo on Day 1 and on Day 29.\n\nPart B: Participants aged 18-54 who choose to be unblinded and received mRNA-1273-matching placebo during Part A, will receive 1 IM injection of 100 ug mRNA-1273 on Day 1 and Day 29.","interventionNames":["Biological: Biological: mRNA-1273","Biological: Placebo"]},{"label":"Placebo (Part A) and mRNA-1273 100 ug (Part B) - Participants Aged 55+ years","type":"PLACEBO_COMPARATOR","description":"Part A: Participants aged 55+ years will receive 1 IM injection of mRNA-1273-matching placebo on Day 1 and on Day 29.\n\nPart B: Participants aged 55+ years who choose to be unblinded and received mRNA-1273-matching placebo during Part A, will receive 1 IM injection of 100 ug mRNA-1273 on Day 1 and Day 29.","interventionNames":["Biological: Biological: mRNA-1273","Biological: Placebo"]},{"label":"mRNA 1273.351 20 ug (Part C)","type":"EXPERIMENTAL","description":"Part C: Participants will receive 1 IM booster dose of 20 ug of mRNA 1273.351 on Day 1.","interventionNames":["Biological: mRNA-1273.351"]},{"label":"mRNA 1273.351 50 ug (Part C)","type":"EXPERIMENTAL","description":"Part C: Participants will receive 1 IM booster dose of 50 ug of mRNA 1273.351 on Day 1.","interventionNames":["Biological: mRNA-1273.351"]},{"label":"mRNA-1273/mRNA-1273.351 mixture (Part C)","type":"EXPERIMENTAL","description":"Part C: Participants will receive 1 IM booster dose of 50 ug of mRNA-1273/mRNA-1273.351 mixture on Day 1.","interventionNames":["Biological: Biological: mRNA-1273","Biological: mRNA-1273.351"]}],"interventions":[{"type":"BIOLOGICAL","name":"Biological: mRNA-1273","description":"Sterile liquid for injection","armGroupLabels":["Placebo (Part A) and mRNA-1273 100 ug (Part B) - Participants Aged 18-54 years","Placebo (Part A) and mRNA-1273 100 ug (Part B) - Participants Aged 55+ years","mRNA-1273/mRNA-1273.351 mixture (Part C)","mRNA-1273: Dose 100 ug - Participants Aged 18-54 years","mRNA-1273: Dose 100 ug - Participants Aged 55+ years","mRNA-1273: Dose 50 microgram (ug) - Participants Aged 18-54 years","mRNA-1273: Dose 50 ug - Participants Aged 55+ years"]},{"type":"BIOLOGICAL","name":"Placebo","description":"0.9% sodium chloride (normal saline) injection","armGroupLabels":["Placebo (Part A) and mRNA-1273 100 ug (Part B) - Participants Aged 18-54 years","Placebo (Part A) and mRNA-1273 100 ug (Part B) - Participants Aged 55+ years"]},{"type":"BIOLOGICAL","name":"mRNA-1273.351","description":"Sterile liquid for injection","armGroupLabels":["mRNA 1273.351 20 ug (Part C)","mRNA 1273.351 50 ug (Part C)","mRNA-1273/mRNA-1273.351 mixture (Part C)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)","description":"Solicited ARs, including local and systemic ARs were collected in the eDiary. Local ARs included: pain at injection site, erythema (redness) at injection site, swelling/induration (hardness) at injection site, and localized axillary swelling or tenderness ipsilateral to the injection arm. Systemic ARs included: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, rash, body temperature (potentially fever), and chills. All solicited ARs (local and systemic) considered causally related to injection. ARs were graded 0-4 as reviewed and confirmed by Investigator; lower score indicates lower severity and a higher score indicates greater severity. Note, not all solicited ARs were considered adverse events (AEs). The Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of SAEs and all nonserious AEs (\"Other\"), regardless of causality, is located in the Reported \"Adverse Events\" section.","timeFrame":"7 days post-vaccination"},{"measure":"Number of Participants With Unsolicited AEs","description":"An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A treatment-emergent AE (TEAE) was defined as any event not present before exposure to vaccine or any event already present that worsens in intensity or frequency after exposure. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \\[PT\\]/partial thromboplastin time \\[PTT\\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsens from baseline and is considered clinically significant in the medical and scientific judgment of the Investigator. A summary of SAEs and all nonserious AEs (\"Other\") reported up to the end of the study (up to Month 15), regardless of causality, is located in the Reported \"Adverse Events\" section.","timeFrame":"Up to 28 days post-vaccination"},{"measure":"Number of Participants With Medically-Attended Adverse Events (MAAEs)","description":"An MAAE is an AE that leads to an unscheduled visit to a healthcare practitioner (HCP). A summary of SAEs and all nonserious AEs (\"Other\"), regardless of causality, is located in the Reported \"Adverse Events\" section.","timeFrame":"Up to Month 15"},{"measure":"Number of Participants With SAEs","description":"An SAE was defined as any AE that resulted in death, is life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs (\"Other\"), regardless of causality, is located in the Reported \"Adverse Events\" section.","timeFrame":"Up to Month 15"},{"measure":"Part A: Level of Severe Acute Respiratory Syndrome Coronavirus (SARS-COV-2)-Specific Binding Antibody (bAb) as Measured by Enzyme-Linked Immunosorbent Assay (ELISA)","description":"The geometric mean (GM) level of VAC58 spike immunoglobulin G (IgG) antibodies, as measured by ELISA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the lower limit of quantification (LLOQ) were replaced by 0.5\\*LLOQ. Values that were greater than the upper limit of quantification (ULOQ) were converted to the ULOQ if actual values were not available. LLOQ was 1 and ULOQ was 2052. The 95% confidence intervals (CIs) were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GM value, respectively, then back transformed to the original scale for presentation.","timeFrame":"Days 1 (Baseline), 29, 43, 57, and 209"},{"measure":"Part B: Level of SARS-CoV-2-Specific bAb as Measured by ELISA","description":"The GM level of VAC65 spike IgG antibodies, as measured by ELISA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\\*LLOQ. Values that were greater than the ULOQ are converted to the ULOQ. LLOQ was 1 and ULOQ was 2052. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GM value, respectively, then back transformed to the original scale for presentation. The PP Set included participants with a study injection, required baseline data, had postinjection results at timepoint of primary interest for immunogenicity analysis, no major protocol deviations impacting immune response, and didn't have SARS-CoV-2.","timeFrame":"Days 1 (Baseline) and 29"},{"measure":"Part C: Level of SARS-CoV-2-Specific bAb as Measured by MSD","description":"The GM level of SARS-CoV-2 protein antibody against B.1.351, as measured by MSD MULTIPLEX is reported. Antibody values reported as below the LLOQ were replaced by 0.5\\*LLOQ. Values that were greater than the ULOQ are converted to the ULOQ. LLOQ was 18 and ULOQ was 4200000. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GM value, respectively, then back transformed to the original scale for presentation.","timeFrame":"Days 1 (Baseline), 8, 15, and 29"}],"secondaryOutcomes":[{"measure":"Part A: Titer of SARS-CoV-2-Specific Neutralizing Antibody (nAb)","description":"The GM titer (microneutralization \\[MN\\] and MN50) of serum nAb against SARS-CoV-2 as measured by live virus MN assays is reported. Antibody values reported as below the LLOQ were replaced by 0.5\\*LLOQ. Values that were greater than the ULOQ were converted to the ULOQ. For MN, LLOQ was 40 and ULOQ was 1280 at Days 1 (Baseline), 29, 43, and 57. For MN50, LLOQ was 91.10 and ULOQ was 2031.87 at Days 1 (Baseline), 29, 43, and 57. For MN, LLOQ was 160 and ULOQ was 1280 at Day 209. For MN50, LLOQ was 318.46 and ULOQ was 1917.83 at Day 209. The 95% CI was calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GM titer, then back transformed to the original scale for presentation.","timeFrame":"Days 1 (Baseline), 29, 43, 57, and 209"},{"measure":"Part B: Titer of SARS-CoV-2-Specific nAb","description":"The GM titer (50% inhibitory dose \\[ID50\\], 80% inhibitory dose \\[ID80\\]) of nAb against SARS-CoV-2 pseudotyped viruses as measured by pseudovirus nAb assay is reported. Antibody values reported as below the LLOQ were replaced by 0.5\\*LLOQ. Values that were greater than the ULOQ were converted to the ULOQ if actual values were not available. LLOQ was 18.5 and ULOQ was 45118 for IC50. LLOQ was 14.3 and ULOQ was 10232 for ID80. The 95% CI was calculated based on the t-distribution of the log-transformed values for GM titer, then back transformed to the original scale for presentation. The PP Set included participants with a study injection, required baseline data, had postinjection results at timepoint of primary interest for immunogenicity analysis, no major protocol deviations impacting immune response, and didn't have SARS-CoV-2.","timeFrame":"Days 1 (Baseline), 29, and 181"},{"measure":"Part C: Titer of SARS-CoV-2-Specific nAb","description":"The GM titer (ID50, ID80) of nAb against SARS-CoV-2 pseudotyped viruses (original strain and beta variant \\[B.1.351\\]) as measured by pseudovirus nAb assay is reported. Antibody values reported as below the LLOQ were replaced by 0.5\\*LLOQ. Values that were greater than the ULOQ were converted to the ULOQ if actual values were not available. For NAb ID50 Titers, LLOQ was 18.5 and ULOQ was 45118. For NAb ID80 Titers, LLOQ was 14.3 and ULOQ was 10232. For NAb ID50 Titers against B.1.351, LLOQ was 19.5 and ULOQ was 385.7. For NAb ID80 Titers against B.1.351, LLOQ was 12.5 and ULOQ was 102.2. The 95% CI was calculated based on the t-distribution of the log-transformed values for GM titer, then back transformed to the original scale for presentation.","timeFrame":"Days 1 (Baseline), 8, 15, 29, and 181"},{"measure":"Part A: Percentage of Participants With Seroconversion From Baseline","description":"Based on MN titers and MN50 titers of serum nAb against SARS-CoV-2 as measured by live virus MN assays, percentage of participants with seroconversion from baseline are reported with 2-sided 95% CI using the Clopper-Pearson method at each post-baseline timepoint. Seroconversion at a participant level was defined as a change of nAb titer from below the limit of detection (LOD) or LLOQ to equal to or above LOD or LLOQ (respectively), or a 4-times or higher titer ratio in participants with pre-existing nAb titers. Antibody values reported as below the LLOQ were replaced by 0.5\\*LLOQ. Values that were greater than the ULOQ were converted to the ULOQ. For MN, LLOQ was 40 and ULOQ was 1280. For MN50, LLOQ was 91.10 and ULOQ was 2031.87.","timeFrame":"Days 29, 43, and 57"},{"measure":"Part B: Percentage of Participants With Seroconversion From Baseline","description":"Based on ID50 and ID80 titers of nAb against SARS-CoV-2 pseudotyped viruses as measured by pseudovirus nAb assay, % of participants with seroconversion from baseline reported with 2-sided 95% CI using Clopper-Pearson method at each postbaseline timepoint. Seroconversion at participant level defined as change of nAb titer from below LOD or LLOQ to equal to or above LOD or LLOQ (respectively) or 4-times or higher titer ratio in participants with preexisting nAb titers. Antibody values \\<LLOQ replaced by 0.5\\*LLOQ. Values \\>ULOQ converted to ULOQ. LLOQ: 18.5 and ULOQ: 45118 for IC50. LLOQ: 14.3 and ULOQ: 10232 for ID80. 95% CI calculated based on t-distribution of log-transformed values for GMT, then back transformed to original scale for presentation. PP Set: participants with a study injection, required baseline data, had postinjection results at timepoint of primary interest for immunogenicity analysis, no major protocol deviations impacting immune response, and didn't have SARS-CoV-2.","timeFrame":"Days 29 and 181"},{"measure":"Part C: Percentage of Participants With Seroconversion From Baseline","description":"Based on ID50 titers and ID80 titers of nAb against SARS-CoV-2 pseudotyped viruses (original strain and beta variant \\[B.1.351\\]) as measured by pseudovirus nAb assay, percentage of participants with seroconversion from baseline are reported with 2-sided 95% CI using Clopper-Pearson method at each post-baseline timepoint. Seroconversion at participant level defined as a change of nAb titer from below LOD or LLOQ ≥LOD or LLOQ (respectively), or a 4-times or higher titer ratio in participants with pre-existing nAb titers. Antibody values reported as below LLOQ were replaced by 0.5\\*LLOQ. Values \\>ULOQ were converted to ULOQ. NAb ID50 Titers: LLOQ was 18.5 and ULOQ was 45118. NAb ID80 Titers: LLOQ was 14.3 and ULOQ was 10232. NAb ID50 Titers against B.1.351: LLOQ was 19.5 and ULOQ was 385.7. NAb ID80 Titers against B.1.351: LLOQ was 12.5 and ULOQ was 102.2. 95% CI calculated based on t-distribution of log-transformed values for GMT, then back transformed to original scale for presentation.","timeFrame":"Days 8, 15, 29, and 181"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\nEach participant must meet all of the following criteria during the screening period and at Day 1, unless noted otherwise, to be enrolled in this study:\n\n1. Male or female, 18 years of age or older at the time of consent (Screening Visit, Day 0). For Part B, participants must have been previously enrolled in the mRNA-1273 P201 study.\n2. Understands and agrees to comply with the study procedures and provides written informed consent.\n3. According to the assessment of the investigator, is in good general health and can comply with study procedures.\n4. Female participants of nonchildbearing potential may be enrolled in the study. Nonchildbearing potential is defined as surgically sterile (history of bilateral tubal ligation, bilateral oophorectomy, hysterectomy) or postmenopausal (defined as amenorrhea for ≥12 consecutive months prior to Screening (Day 0) without an alternative medical cause). A follicle-stimulating hormone (FSH) level may be measured at the discretion of the investigator to confirm postmenopausal status.\n5. Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the following criteria:\n\n   * Has a negative pregnancy test at Screening (Day 0) and on the day of the first injection (Day 1).\n   * Has practiced adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first injection (Day 1).\n   * Has agreed to continue adequate contraception through 3 months following the second injection (Day 29).\n   * Is not currently breastfeeding.\n\n   Adequate female contraception is defined as consistent and correct use of a Food and Drug Administration (FDA) approved contraceptive method in accordance with the product label. For example:\n   * Barrier method (such as condoms, diaphragm, or cervical cap) used in conjunction with spermicide\n   * Intrauterine device\n   * Prescription hormonal contraceptive taken or administered via oral (pill), transdermal (patch), subdermal, or IM route\n   * Sterilization of a female participant's monogamous male partner prior to entry into the study Note: periodic abstinence (for example, calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.\n6. Male participants engaging in activity that could result in pregnancy of sexual partners must agree to practice adequate contraception from the time of the first injection and through 3 months after the last injection.\n\nAdequate contraception for male participants is defined as:\n\n* Monogamous relationship with a female partner using an intrauterine device or hormonal contraception (described above)\n* Use of barrier methods and spermicide\n* History of surgical sterilization\n* Male participants with partners who have become pregnant prior to Screening are eligible to participate in the study.\n\nAdditional Key Inclusion Criteria for Part C\n\n1\\. Participants must have been previously enrolled in the mRNA-1273-P301 study and must have received 2 doses of mRNA-1273 in Part A, has been unblinded and aware of their actual treatment in Study mRNA-1273-P301, must have been compliant in Study mRNA-1273-P301 (was not withdrawn or discontinued early), and has been at least 6 months since their second dose in Study mRNA-1273-P301 prior to enrollment in this part.\n\nKey Exclusion Criteria:\n\nParticipants meeting any of the following criteria at the Screening Visit (Day 0) or at Day 1, unless noted otherwise, will be excluded from the study:\n\n1. Pregnant or breastfeeding.\n2. Is acutely ill or febrile 24 hours prior to or at the Screening Visit (Day 0). Fever is defined as a body temperature ≥38.0°Celsius/100.4°Fahrenheit. Participants meeting this criterion may be rescheduled within the relevant window periods. Afebrile participants with minor illnesses can be enrolled at the discretion of the investigator.\n3. Current treatment with investigational agents for prophylaxis against COVID-19.\n4. Has a medical, psychiatric, or occupational condition that may pose additional risk as a result of participation, or that could interfere with safety assessments or interpretation of results according to the investigator's judgment.\n5. Is a healthcare worker or a member of an emergency response team.\n6. Current use of any inhaled substance (for example, tobacco or cannabis smoke, nicotine vapors).\n7. History of chronic smoking (≥1 cigarette a day) within 1 year of the Screening Visit (Day 0).\n8. History of illegal substance use or alcohol abuse within the past 2 years. This exclusion does not apply to historical cannabis use that was formerly illegal in the participant's state but is legal at the time of Screening.\n9. Known history of hypertension, or systolic blood pressure \\>150 millimeter of mercury (mmHg) in participants in Cohort 1 (≥18 to \\<55 years old) or systolic blood pressure \\>160 mmHg in participants in Cohort 2 (≥55 years old) at the Screening Visit (Day 0).\n10. Known history of hypotension or systolic blood pressure \\<85 mmHg at the Screening Visit (Day 0).\n11. Diabetes mellitus\n12. Diagnosis of chronic pulmonary disease (for example, chronic obstructive pulmonary disease, asthma)\n13. Chronic cardiovascular disease\n14. Resides in a nursing home\n15. Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)\n16. Current or previous diagnosis of immunocompromising condition, immune-mediated disease, or other immunosuppressive condition.\n17. Received systemic immunosuppressants or immune-modifying drugs for \\>14 days in total within 6 months prior to the Screening Visit (Day 0) (for corticosteroids ≥20 milligrams (mg)/day of prednisone equivalent). Topical tacrolimus is allowed if not used within 14 days prior to the Screening Visit (Day 0).\n18. Anticipating the need for immunosuppressive treatment at any time during participation in the study.\n19. Positive serology for hepatitis B virus surface antigen, hepatitis C virus antibody, or human immunodeficiency virus (HIV) type 1 or 2 antibodies identified at the Screening Visit (Day 0).\n20. History of anaphylaxis, urticaria, or other significant AR requiring medical intervention after receipt of a vaccine.\n21. Bleeding disorder considered a contraindication to IM injection or phlebotomy.\n22. Diagnosis of malignancy within previous 10 years (excluding non-melanoma skin cancer).\n23. Has received or plans to receive a licensed vaccine ≤28 days prior to the first injection (Day 1) or plans to receive a licensed vaccine within 28 days before or after any study injection. Licensed influenza vaccines may be received more than 14 days before or after any study injection.\n24. Receipt of systemic immunoglobulins or blood products within 3 months prior to the Screening Visit (Day 0) or plans for receipt during the study.\n25. Has donated ≥450 mL of blood products within 28 days prior to the Screening Visit (Day 0) or plans to donate blood products during the study.\n26. Participated in an interventional clinical study (other than mRNA-1273 P301) within 28 days prior to the Screening Visit (Day 0) or plans to do so while participating in this study.\n27. Is an immediate family member or household member of study personnel\n\nAdditional Key Exclusion Criteria for Part C\n\n1. Is SARS-CoV-2 positive by Reverse transcription polymerase chain reaction (RT-PCR) (central or local testing) at baseline or at any time during the mRNA-1273-P301 study regardless of the presence or absence of symptoms consistent with COVID-19.\n2. Had any SAE in the mRNA-1273-P301 study.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Meridian Clinical Research","city":"Savannah","state":"Georgia","zip":"31406","country":"United States","geoPoint":{"lat":32.08354,"lon":-81.09983}},{"facility":"Alliance for Multispecialty Research","city":"Newton","state":"Kansas","zip":"67114","country":"United States","geoPoint":{"lat":38.04668,"lon":-97.34504}},{"facility":"Alliance for Multispecialty Research","city":"Kansas City","state":"Missouri","zip":"64114","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"Meridian Clinical Research","city":"Norfolk","state":"Nebraska","zip":"68701","country":"United States","geoPoint":{"lat":42.02834,"lon":-97.417}},{"facility":"Trial Management Associates","city":"Wilmington","state":"North Carolina","zip":"28403","country":"United States","geoPoint":{"lat":34.23556,"lon":-77.94604}},{"facility":"Meridian Clinical Research","city":"Dakota Dunes","state":"South Dakota","zip":"57049","country":"United States","geoPoint":{"lat":42.48749,"lon":-96.48642}},{"facility":"Benchmark Research","city":"Austin","state":"Texas","zip":"78705","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"Benchmark Research","city":"San Angelo","state":"Texas","zip":"76904","country":"United States","geoPoint":{"lat":31.46377,"lon":-100.43704}}]},"referencesModule":{"references":[{"pmid":"36376733","type":"DERIVED","citation":"Kirste I, Hortsch S, Grunert VP, Legault H, Maglinao M, Eichenlaub U, Kashlan B, Pajon R, Jochum S. Quantifying the Vaccine-Induced Humoral Immune Response to Spike-Receptor Binding Domain as a Surrogate for Neutralization Testing Following mRNA-1273 (Spikevax) Vaccination Against COVID-19. Infect Dis Ther. 2023 Jan;12(1):177-191. doi: 10.1007/s40121-022-00711-y. Epub 2022 Nov 15."},{"pmid":"36202997","type":"DERIVED","citation":"Chalkias S, Eder F, Essink B, Khetan S, Nestorova B, Feng J, Chen X, Chang Y, Zhou H, Montefiori D, Edwards DK, Girard B, Pajon R, Dutko FJ, Leav B, Walsh SR, Baden LR, Miller JM, Das R. Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial. Nat Med. 2022 Nov;28(11):2388-2397. doi: 10.1038/s41591-022-02031-7. Epub 2022 Oct 6."},{"pmid":"35241844","type":"DERIVED","citation":"Chu L, Vrbicky K, Montefiori D, Huang W, Nestorova B, Chang Y, Carfi A, Edwards DK, Oestreicher J, Legault H, Dutko FJ, Girard B, Pajon R, Miller JM, Das R, Leav B, McPhee R. Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial. Nat Med. 2022 May;28(5):1042-1049. doi: 10.1038/s41591-022-01739-w. Epub 2022 Mar 3."},{"pmid":"34526698","type":"DERIVED","citation":"Choi A, Koch M, Wu K, Chu L, Ma L, Hill A, Nunna N, Huang W, Oestreicher J, Colpitts T, Bennett H, Legault H, Paila Y, Nestorova B, Ding B, Montefiori D, Pajon R, Miller JM, Leav B, Carfi A, McPhee R, Edwards DK. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. Nat Med. 2021 Nov;27(11):2025-2031. doi: 10.1038/s41591-021-01527-y. Epub 2021 Sep 15."},{"pmid":"33707061","type":"DERIVED","citation":"Chu L, McPhee R, Huang W, Bennett H, Pajon R, Nestorova B, Leav B; mRNA-1273 Study Group. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine. 2021 May 12;39(20):2791-2799. doi: 10.1016/j.vaccine.2021.02.007. Epub 2021 Feb 9."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Part A participants received 50 microgram (µg) mRNA-1273, 100 µg mRNA-1273, or placebo (N=600). Participants who received placebo in Part A, received 100 ug mRNA-1273 in Part B (N=158). Participants who received 50 or 100 ug mRNA-1273 in Part A, received 50 ug mRNA-1273 in Part B (N=344). Participants in Part C (N=60) received a booster dose of 20 or 50 µg of mRNA-1273.351 or 50 µg mRNA-1273/mRNA-1273.351 mixture. Total number of enrolled participants for the study=660.","recruitmentDetails":"Participants in Part A were blinded to study treatment. After completion of Part A, participants could have chosen to be unblinded and to participate in Part B (open-label). Participants in Part C (proof-of-concept rollover) were unblinded and had received 2 doses of mRNA-1273 in Study mRNA-1273-P301 (Study P301; NCT04470427).","groups":[{"id":"FG000","title":"Part A: 50 ug mRNA-1273","description":"Participants received 1 intramuscular (IM) injection of 50 ug mRNA-1273 on Day 1 and on Day 29."},{"id":"FG001","title":"Part A: 100 ug mRNA-1273","description":"Participants received 1 IM injection of 100 ug mRNA-1273 on Day 1 and on Day 29."},{"id":"FG002","title":"Part A: Placebo","description":"Participants received 1 IM injection of mRNA-1273-matching placebo on Day 1 and on Day 29."},{"id":"FG003","title":"Part B: 50 ug mRNA-1273 Then 50 ug mRNA-1273","description":"Participants who chose to be unblinded and received 50 ug mRNA-1273 during Part A, received 1 IM injection of 50 ug mRNA-1273 during Part B."},{"id":"FG004","title":"Part B: 100 ug mRNA-1273 Then 50 ug mRNA-1273","description":"Participants who chose to be unblinded and received 100 ug mRNA-1273 during Part A, received 1 IM injection of 50 ug mRNA-1273 during Part B."},{"id":"FG005","title":"Part B: Placebo Then 100 ug mRNA-1273","description":"Participants who chose to be unblinded and received mRNA-1273-matching placebo during Part A, received 2 IM injections of 100 ug mRNA-1273 28 days apart during Part B."},{"id":"FG006","title":"Part C: 20 ug mRNA-1273.351","description":"Participants received 1 IM injection of 20 ug mRNA-1273.351 (booster dose) on Day 1."},{"id":"FG007","title":"Part C: 50 ug mRNA-1273.351","description":"Participants received 1 IM injection of 50 ug mRNA-1273.351 (booster dose) on Day 1."},{"id":"FG008","title":"Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture","description":"Participants received 1 IM injection of 50 ug mRNA-1273/mRNA-1273.351 mixture (booster dose) on Day 1."}],"periods":[{"title":"Part A (Blinded Phase)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"200"},{"groupId":"FG001","numSubjects":"200"},{"groupId":"FG002","numSubjects":"200"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"}]},{"type":"Received at Least 1 Dose of Study Drug During Part A","achievements":[{"groupId":"FG000","numSubjects":"200"},{"groupId":"FG001","numSubjects":"200"},{"groupId":"FG002","numSubjects":"200"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"188"},{"groupId":"FG001","numSubjects":"185"},{"groupId":"FG002","numSubjects":"182"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"15"},{"groupId":"FG002","numSubjects":"18"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"7"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"8"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"}]},{"type":"Withdrawal of consent (COVID-19 non-infection related)","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"}]},{"type":"Withdrawal of consent (other)","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"}]},{"type":"Other than Specified","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"}]}]},{"title":"Part B (Open-Label Interventional Phase)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"173"},{"groupId":"FG004","numSubjects":"171"},{"groupId":"FG005","numSubjects":"158"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"}]},{"type":"Received at Least 1 Dose of Study Drug During Part B","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"173"},{"groupId":"FG004","numSubjects":"171"},{"groupId":"FG005","numSubjects":"158"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"161"},{"groupId":"FG004","numSubjects":"166"},{"groupId":"FG005","numSubjects":"152"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"12"},{"groupId":"FG004","numSubjects":"5"},{"groupId":"FG005","numSubjects":"6"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"4"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"}]}]},{"title":"Part C (Rollover Proof of Concept)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"20"},{"groupId":"FG007","numSubjects":"20"},{"groupId":"FG008","numSubjects":"20"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"18"},{"groupId":"FG007","numSubjects":"18"},{"groupId":"FG008","numSubjects":"19"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"2"},{"groupId":"FG007","numSubjects":"2"},{"groupId":"FG008","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Withdrawal of consent (other)","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"2"},{"groupId":"FG008","numSubjects":"1"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"2"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Safety Set: All participants who received any study injection in their respective part of the study. Note, participants who received placebo in Part A, received 100 ug mRNA-1273 in Part B (N=158). Participants who received 50 or 100 ug mRNA-1273 in Part A, received 50 ug mRNA-1273 in Part B (N=344). Since Baseline Characteristics data for participants in Part B are included in Part A, separate columns are not reported here for Part B.","groups":[{"id":"BG000","title":"Part A: 50 ug mRNA-1273","description":"Participants received 1 IM injection of 50 ug mRNA-1273 on Day 1 and on Day 29."},{"id":"BG001","title":"Part A: 100 ug mRNA-1273","description":"Participants received 1 IM injection of 100 ug mRNA-1273 on Day 1 and on Day 29."},{"id":"BG002","title":"Part A: Placebo","description":"Participants received 1 IM injection of mRNA-1273-matching placebo on Day 1 and on Day 29."},{"id":"BG003","title":"Part C: 20 ug mRNA-1273.351","description":"Participants received 1 IM injection of 20 ug mRNA-1273.351 (booster dose) on Day 1."},{"id":"BG004","title":"Part C: 50 ug mRNA-1273.351","description":"Participants received 1 IM injection of 50 ug mRNA-1273.351 (booster dose) on Day 1."},{"id":"BG005","title":"Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture","description":"Participants received 1 IM injection of 50 ug mRNA-1273/mRNA-1273.351 mixture (booster dose) on Day 1."},{"id":"BG006","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"200"},{"groupId":"BG001","value":"200"},{"groupId":"BG002","value":"200"},{"groupId":"BG003","value":"20"},{"groupId":"BG004","value":"20"},{"groupId":"BG005","value":"20"},{"groupId":"BG006","value":"660"}]}],"measures":[{"title":"Age, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Between 18 and 55 years","measurements":[{"groupId":"BG000","value":"100"},{"groupId":"BG001","value":"100"},{"groupId":"BG002","value":"100"},{"groupId":"BG003","value":"13"},{"groupId":"BG004","value":"9"},{"groupId":"BG005","value":"9"},{"groupId":"BG006","value":"331"}]},{"title":">=55 years","measurements":[{"groupId":"BG000","value":"100"},{"groupId":"BG001","value":"100"},{"groupId":"BG002","value":"100"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"11"},{"groupId":"BG005","value":"11"},{"groupId":"BG006","value":"329"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"137"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"129"},{"groupId":"BG003","value":"15"},{"groupId":"BG004","value":"9"},{"groupId":"BG005","value":"8"},{"groupId":"BG006","value":"422"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"76"},{"groupId":"BG002","value":"71"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"11"},{"groupId":"BG005","value":"12"},{"groupId":"BG006","value":"238"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"16"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"49"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"184"},{"groupId":"BG001","value":"184"},{"groupId":"BG002","value":"184"},{"groupId":"BG003","value":"19"},{"groupId":"BG004","value":"20"},{"groupId":"BG005","value":"19"},{"groupId":"BG006","value":"610"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"188"},{"groupId":"BG001","value":"188"},{"groupId":"BG002","value":"193"},{"groupId":"BG003","value":"20"},{"groupId":"BG004","value":"19"},{"groupId":"BG005","value":"19"},{"groupId":"BG006","value":"627"}]}]},{"title":"Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"16"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"8"}]}]},{"title":"American Indian or Alaska Native","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"4"}]}]},{"title":"Native Hawaiian or Other Pacific Islander","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"}]}]},{"title":"Multiracial","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"2"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"2"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)","description":"Solicited ARs, including local and systemic ARs were collected in the eDiary. Local ARs included: pain at injection site, erythema (redness) at injection site, swelling/induration (hardness) at injection site, and localized axillary swelling or tenderness ipsilateral to the injection arm. Systemic ARs included: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, rash, body temperature (potentially fever), and chills. All solicited ARs (local and systemic) considered causally related to injection. ARs were graded 0-4 as reviewed and confirmed by Investigator; lower score indicates lower severity and a higher score indicates greater severity. Note, not all solicited ARs were considered adverse events (AEs). The Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of SAEs and all nonserious AEs (\"Other\"), regardless of causality, is located in the Reported \"Adverse Events\" section.","populationDescription":"Solicited Safety Set for Parts A, B, and C included all participants who received any study injection in the applicable part of the study and contributed any solicited AR data (that is, had at least 1 post-baseline solicited safety assessment in the applicable part of the study). Number Analyzed = participants who were evaluable at specified timepoints.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"7 days post-vaccination","groups":[{"id":"OG000","title":"Part A: 50 ug mRNA-1273","description":"Participants received 1 IM injection of 50 ug mRNA-1273 on Day 1 and on Day 29."},{"id":"OG001","title":"Part A: 100 ug mRNA-1273","description":"Participants received 1 IM injection of 100 ug mRNA-1273 on Day 1 and on Day 29."},{"id":"OG002","title":"Part A: Placebo","description":"Participants received 1 IM injection of mRNA-1273-matching placebo on Day 1 and on Day 29."},{"id":"OG003","title":"Part B: 50 ug mRNA-1273 Then 50 ug mRNA-1273","description":"Participants who chose to be unblinded and received 50 ug mRNA-1273 during Part A, received 1 IM injection of 50 ug mRNA-1273 during Part B."},{"id":"OG004","title":"Part B: 100 ug mRNA-1273 Then 50 ug mRNA-1273","description":"Participants who chose to be unblinded and received 100 ug mRNA-1273 during Part A, received 1 IM injection of 50 ug mRNA-1273 during Part B."},{"id":"OG005","title":"Part B: Placebo Then 100 ug mRNA-1273","description":"Participants who chose to be unblinded and received mRNA-1273-matching placebo during Part A, received 2 IM injections of 100 ug mRNA-1273 28 days apart during Part B."},{"id":"OG006","title":"Part C: 20 ug mRNA-1273.351","description":"Participants received 1 IM injection of 20 ug mRNA-1273.351 (booster dose) on Day 1."},{"id":"OG007","title":"Part C: 50 ug mRNA-1273.351","description":"Participants received 1 IM injection of 50 ug mRNA-1273.351 (booster dose) on Day 1."},{"id":"OG008","title":"Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture","description":"Participants received 1 IM injection of 50 ug mRNA-1273/mRNA-1273.351 mixture (booster dose) on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"200"},{"groupId":"OG002","value":"200"},{"groupId":"OG003","value":"164"},{"groupId":"OG004","value":"167"},{"groupId":"OG005","value":"157"},{"groupId":"OG006","value":"19"},{"groupId":"OG007","value":"19"},{"groupId":"OG008","value":"20"}]}],"classes":[{"title":"Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"69"},{"groupId":"OG002","value":"72"},{"groupId":"OG003","value":"65"},{"groupId":"OG004","value":"73"},{"groupId":"OG005","value":"50"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"10"},{"groupId":"OG008","value":"12"}]}]},{"title":"Grade 2","categories":[{"measurements":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"90"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"59"},{"groupId":"OG004","value":"59"},{"groupId":"OG005","value":"71"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"3"}]}]},{"title":"Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"29"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"28"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"2"}]}]},{"title":"Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Unsolicited AEs","description":"An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A treatment-emergent AE (TEAE) was defined as any event not present before exposure to vaccine or any event already present that worsens in intensity or frequency after exposure. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \\[PT\\]/partial thromboplastin time \\[PTT\\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsens from baseline and is considered clinically significant in the medical and scientific judgment of the Investigator. A summary of SAEs and all nonserious AEs (\"Other\") reported up to the end of the study (up to Month 15), regardless of causality, is located in the Reported \"Adverse Events\" section.","populationDescription":"Safety Set: All participants who received any study injection in their respective part of the study.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 28 days post-vaccination","groups":[{"id":"OG000","title":"Part A: 50 ug mRNA-1273","description":"Participants received 1 IM injection of 50 ug mRNA-1273 on Day 1 and on Day 29."},{"id":"OG001","title":"Part A: 100 ug mRNA-1273","description":"Participants received 1 IM injection of 100 ug mRNA-1273 on Day 1 and on Day 29."},{"id":"OG002","title":"Part A: Placebo","description":"Participants received 1 IM injection of mRNA-1273-matching placebo on Day 1 and on Day 29."},{"id":"OG003","title":"Part B: 50 ug mRNA-1273 Then 50 ug mRNA-1273","description":"Participants who chose to be unblinded and received 50 ug mRNA-1273 during Part A, received 1 IM injection of 50 ug mRNA-1273 during Part B."},{"id":"OG004","title":"Part B: 100 ug mRNA-1273 Then 50 ug mRNA-1273","description":"Participants who chose to be unblinded and received 100 ug mRNA-1273 during Part A, received 1 IM injection of 50 ug mRNA-1273 during Part B."},{"id":"OG005","title":"Part B: Placebo Then 100 ug mRNA-1273","description":"Participants who chose to be unblinded and received mRNA-1273-matching placebo during Part A, received 2 IM injections of 100 ug mRNA-1273 28 days apart during Part B."},{"id":"OG006","title":"Part C: 20 ug mRNA-1273.351","description":"Participants received 1 IM injection of 20 ug mRNA-1273.351 (booster dose) on Day 1."},{"id":"OG007","title":"Part C: 50 ug mRNA-1273.351","description":"Participants received 1 IM injection of 50 ug mRNA-1273.351 (booster dose) on Day 1."},{"id":"OG008","title":"Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture","description":"Participants received 1 IM injection of 50 ug mRNA-1273/mRNA-1273.351 mixture (booster dose) on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"200"},{"groupId":"OG002","value":"200"},{"groupId":"OG003","value":"173"},{"groupId":"OG004","value":"171"},{"groupId":"OG005","value":"158"},{"groupId":"OG006","value":"20"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"51"},{"groupId":"OG003","value":"17"},{"groupId":"OG004","value":"25"},{"groupId":"OG005","value":"42"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"4"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Medically-Attended Adverse Events (MAAEs)","description":"An MAAE is an AE that leads to an unscheduled visit to a healthcare practitioner (HCP). A summary of SAEs and all nonserious AEs (\"Other\"), regardless of causality, is located in the Reported \"Adverse Events\" section.","populationDescription":"Safety Set: All participants who received any study injection in their respective part of the study.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 15","groups":[{"id":"OG000","title":"Part A: 50 ug mRNA-1273","description":"Participants received 1 IM injection of 50 ug mRNA-1273 on Day 1 and on Day 29."},{"id":"OG001","title":"Part A: 100 ug mRNA-1273","description":"Participants received 1 IM injection of 100 ug mRNA-1273 on Day 1 and on Day 29."},{"id":"OG002","title":"Part A: Placebo","description":"Participants received 1 IM injection of mRNA-1273-matching placebo on Day 1 and on Day 29."},{"id":"OG003","title":"Part B: 50 ug mRNA-1273 Then 50 ug mRNA-1273","description":"Participants who chose to be unblinded and received 50 ug mRNA-1273 during Part A, received 1 IM injection of 50 ug mRNA-1273 during Part B."},{"id":"OG004","title":"Part B: 100 ug mRNA-1273 Then 50 ug mRNA-1273","description":"Participants who chose to be unblinded and received 100 ug mRNA-1273 during Part A, received 1 IM injection of 50 ug mRNA-1273 during Part B."},{"id":"OG005","title":"Part B: Placebo Then 100 ug mRNA-1273","description":"Participants who chose to be unblinded and received mRNA-1273-matching placebo during Part A, received 2 IM injections of 100 ug mRNA-1273 28 days apart during Part B."},{"id":"OG006","title":"Part C: 20 ug mRNA-1273.351","description":"Participants received 1 IM injection of 20 ug mRNA-1273.351 (booster dose) on Day 1."},{"id":"OG007","title":"Part C: 50 ug mRNA-1273.351","description":"Participants received 1 IM injection of 50 ug mRNA-1273.351 (booster dose) on Day 1."},{"id":"OG008","title":"Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture","description":"Participants received 1 IM injection of 50 ug mRNA-1273/mRNA-1273.351 mixture (booster dose) on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"200"},{"groupId":"OG002","value":"200"},{"groupId":"OG003","value":"173"},{"groupId":"OG004","value":"171"},{"groupId":"OG005","value":"158"},{"groupId":"OG006","value":"20"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"38"},{"groupId":"OG002","value":"64"},{"groupId":"OG003","value":"42"},{"groupId":"OG004","value":"47"},{"groupId":"OG005","value":"59"},{"groupId":"OG006","value":"7"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"7"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With SAEs","description":"An SAE was defined as any AE that resulted in death, is life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs (\"Other\"), regardless of causality, is located in the Reported \"Adverse Events\" section.","populationDescription":"Safety Set: All participants who received any study injection in their respective part of the study.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Month 15","groups":[{"id":"OG000","title":"Part A: 50 ug mRNA-1273","description":"Participants received 1 IM injection of 50 ug mRNA-1273 on Day 1 and on Day 29."},{"id":"OG001","title":"Part A: 100 ug mRNA-1273","description":"Participants received 1 IM injection of 100 ug mRNA-1273 on Day 1 and on Day 29."},{"id":"OG002","title":"Part A: Placebo","description":"Participants received 1 IM injection of mRNA-1273-matching placebo on Day 1 and on Day 29."},{"id":"OG003","title":"Part B: 50 ug mRNA-1273 Then 50 ug mRNA-1273","description":"Participants who chose to be unblinded and received 50 ug mRNA-1273 during Part A, received 1 IM injection of 50 ug mRNA-1273 during Part B."},{"id":"OG004","title":"Part B: 100 ug mRNA-1273 Then 50 ug mRNA-1273","description":"Participants who chose to be unblinded and received 100 ug mRNA-1273 during Part A, received 1 IM injection of 50 ug mRNA-1273 during Part B."},{"id":"OG005","title":"Part B: Placebo Then 100 ug mRNA-1273","description":"Participants who chose to be unblinded and received mRNA-1273-matching placebo during Part A, received 2 IM injections of 100 ug mRNA-1273 28 days apart during Part B."},{"id":"OG006","title":"Part C: 20 ug mRNA-1273.351","description":"Participants received 1 IM injection of 20 ug mRNA-1273.351 (booster dose) on Day 1."},{"id":"OG007","title":"Part C: 50 ug mRNA-1273.351","description":"Participants received 1 IM injection of 50 ug mRNA-1273.351 (booster dose) on Day 1."},{"id":"OG008","title":"Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture","description":"Participants received 1 IM injection of 50 ug mRNA-1273/mRNA-1273.351 mixture (booster dose) on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"200"},{"groupId":"OG002","value":"200"},{"groupId":"OG003","value":"173"},{"groupId":"OG004","value":"171"},{"groupId":"OG005","value":"158"},{"groupId":"OG006","value":"20"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"0"}]}]}]},{"type":"PRIMARY","title":"Part A: Level of Severe Acute Respiratory Syndrome Coronavirus (SARS-COV-2)-Specific Binding Antibody (bAb) as Measured by Enzyme-Linked Immunosorbent Assay (ELISA)","description":"The geometric mean (GM) level of VAC58 spike immunoglobulin G (IgG) antibodies, as measured by ELISA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the lower limit of quantification (LLOQ) were replaced by 0.5\\*LLOQ. Values that were greater than the upper limit of quantification (ULOQ) were converted to the ULOQ if actual values were not available. LLOQ was 1 and ULOQ was 2052. The 95% confidence intervals (CIs) were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GM value, respectively, then back transformed to the original scale for presentation.","populationDescription":"Per-Protocol (PP) Set included randomized participants who received any study injection, had required baseline (Day 1) data, had ≥1 post-injection assessment for the analysis endpoint, complied with injection schedule, had post-injection results available for ≥1 assay component corresponding to immunogenicity analysis, did not have SARS-CoV-2 infection, and had no major protocol deviations impacting applicable immune response. Number Analyzed = participants evaluable at specified timepoints.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"arbitrary units per mL (AU/mL)","timeFrame":"Days 1 (Baseline), 29, 43, 57, and 209","groups":[{"id":"OG000","title":"Part A: 50 ug mRNA-1273","description":"Participants received 1 IM injection of 50 ug mRNA-1273 on Day 1 and on Day 29."},{"id":"OG001","title":"Part A: 100 ug mRNA-1273","description":"Participants received 1 IM injection of 100 ug mRNA-1273 on Day 1 and on Day 29."},{"id":"OG002","title":"Part A: Placebo","description":"Participants received 1 IM injection of mRNA-1273-matching placebo on Day 1 and on Day 29."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"189"},{"groupId":"OG002","value":"186"}]}],"classes":[{"title":"Day 1 (Baseline)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"189"},{"groupId":"OG002","value":"186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.70","lowerLimit":"0.63","upperLimit":"0.78"},{"groupId":"OG001","value":"0.67","lowerLimit":"0.60","upperLimit":"0.73"},{"groupId":"OG002","value":"0.67","lowerLimit":"0.61","upperLimit":"0.73"}]}]},{"title":"Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"189"},{"groupId":"OG002","value":"182"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"59.42","lowerLimit":"52.05","upperLimit":"67.82"},{"groupId":"OG001","value":"81.51","lowerLimit":"70.19","upperLimit":"94.67"},{"groupId":"OG002","value":"0.68","lowerLimit":"0.61","upperLimit":"0.76"}]}]},{"title":"Day 43","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"176"},{"groupId":"OG001","value":"180"},{"groupId":"OG002","value":"180"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"720.85","lowerLimit":"660.30","upperLimit":"786.96"},{"groupId":"OG001","value":"834.66","lowerLimit":"765.28","upperLimit":"910.33"},{"groupId":"OG002","value":"0.65","lowerLimit":"0.59","upperLimit":"0.71"}]}]},{"title":"Day 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"176"},{"groupId":"OG001","value":"174"},{"groupId":"OG002","value":"174"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"519.48","lowerLimit":"474.00","upperLimit":"569.33"},{"groupId":"OG001","value":"647.22","lowerLimit":"588.98","upperLimit":"711.21"},{"groupId":"OG002","value":"0.67","lowerLimit":"0.60","upperLimit":"0.75"}]}]},{"title":"Day 209","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"174"},{"groupId":"OG002","value":"154"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97.02","lowerLimit":"87.58","upperLimit":"107.47"},{"groupId":"OG001","value":"128.00","lowerLimit":"114.44","upperLimit":"143.18"},{"groupId":"OG002","value":"0.91","lowerLimit":"0.73","upperLimit":"1.14"}]}]}]},{"type":"PRIMARY","title":"Part B: Level of SARS-CoV-2-Specific bAb as Measured by ELISA","description":"The GM level of VAC65 spike IgG antibodies, as measured by ELISA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\\*LLOQ. Values that were greater than the ULOQ are converted to the ULOQ. LLOQ was 1 and ULOQ was 2052. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GM value, respectively, then back transformed to the original scale for presentation. The PP Set included participants with a study injection, required baseline data, had postinjection results at timepoint of primary interest for immunogenicity analysis, no major protocol deviations impacting immune response, and didn't have SARS-CoV-2.","populationDescription":"PP Set. Number Analyzed=participants evaluable at specified timepoint. Immunogenicity samples from the \"Part B: Placebo then 100 ug mRNA\" arm were not tested and no data were generated as results were not thought to provide additional information. After Part B samples were obtained, it was determined that the extensive results for immunogenicity profiles of 2 doses of 100 ug mRNA-1273 that were obtained during Part A of this study and in Study P301 demonstrated enough immune response data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"AU/mL","timeFrame":"Days 1 (Baseline) and 29","groups":[{"id":"OG000","title":"Part B: 50 ug mRNA-1273 Then 50 ug mRNA-1273","description":"Participants who chose to be unblinded and received 50 ug mRNA-1273 during Part A, received 1 IM injection of 50 ug mRNA-1273 during Part B."},{"id":"OG001","title":"Part B: 100 ug mRNA-1273 Then 50 ug mRNA-1273","description":"Participants who chose to be unblinded and received 100 ug mRNA-1273 during Part A, received 1 IM injection of 50 ug mRNA-1273 during Part B."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"149"}]}],"classes":[{"title":"Day 1 (Baseline)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"145"},{"groupId":"OG001","value":"147"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86.29","lowerLimit":"76.89","upperLimit":"96.83"},{"groupId":"OG001","value":"109.56","lowerLimit":"96.79","upperLimit":"124.02"}]}]},{"title":"Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"149"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1069.73","lowerLimit":"992.92","upperLimit":"1152.49"},{"groupId":"OG001","value":"1083.21","lowerLimit":"1018.75","upperLimit":"1151.75"}]}]}]},{"type":"SECONDARY","title":"Part A: Titer of SARS-CoV-2-Specific Neutralizing Antibody (nAb)","description":"The GM titer (microneutralization \\[MN\\] and MN50) of serum nAb against SARS-CoV-2 as measured by live virus MN assays is reported. Antibody values reported as below the LLOQ were replaced by 0.5\\*LLOQ. Values that were greater than the ULOQ were converted to the ULOQ. For MN, LLOQ was 40 and ULOQ was 1280 at Days 1 (Baseline), 29, 43, and 57. For MN50, LLOQ was 91.10 and ULOQ was 2031.87 at Days 1 (Baseline), 29, 43, and 57. For MN, LLOQ was 160 and ULOQ was 1280 at Day 209. For MN50, LLOQ was 318.46 and ULOQ was 1917.83 at Day 209. The 95% CI was calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GM titer, then back transformed to the original scale for presentation.","populationDescription":"PP Set included randomized participants who received any study injection, had required baseline (Day 1) data, had ≥1 post-injection assessment for the analysis endpoint, complied with injection schedule, had post-injection results available for ≥1 assay component corresponding to immunogenicity analysis, did not have SARS-CoV-2 infection, and had no major protocol deviations impacting applicable immune response. Number Analyzed = participants who were evaluable at specified timepoints.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titers","timeFrame":"Days 1 (Baseline), 29, 43, 57, and 209","groups":[{"id":"OG000","title":"Part A: 50 ug mRNA-1273","description":"Participants received 1 IM injection of 50 ug mRNA-1273 on Day 1 and on Day 29."},{"id":"OG001","title":"Part A: 100 ug mRNA-1273","description":"Participants received 1 IM injection of 100 ug mRNA-1273 on Day 1 and on Day 29."},{"id":"OG002","title":"Part A: Placebo","description":"Participants received 1 IM injection of mRNA-1273-matching placebo on Day 1 and on Day 29."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"189"},{"groupId":"OG002","value":"186"}]}],"classes":[{"title":"MN, Day 1 (Baseline)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"189"},{"groupId":"OG002","value":"186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.6","lowerLimit":"20.0","upperLimit":"21.2"},{"groupId":"OG001","value":"20.6","lowerLimit":"19.7","upperLimit":"21.5"},{"groupId":"OG002","value":"20.8","lowerLimit":"20.1","upperLimit":"21.4"}]}]},{"title":"MN, Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"187"},{"groupId":"OG002","value":"184"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"112.2","lowerLimit":"94.9","upperLimit":"132.7"},{"groupId":"OG001","value":"149.6","lowerLimit":"127.3","upperLimit":"175.9"},{"groupId":"OG002","value":"21.9","lowerLimit":"20.5","upperLimit":"23.5"}]}]},{"title":"MN, Day 43","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"174"},{"groupId":"OG001","value":"181"},{"groupId":"OG002","value":"180"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1145.4","lowerLimit":"1101.3","upperLimit":"1191.1"},{"groupId":"OG001","value":"1185.8","lowerLimit":"1142.9","upperLimit":"1230.3"},{"groupId":"OG002","value":"21.2","lowerLimit":"20.1","upperLimit":"22.4"}]}]},{"title":"MN, Day 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"176"},{"groupId":"OG001","value":"177"},{"groupId":"OG002","value":"175"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1090.6","lowerLimit":"1038.9","upperLimit":"1144.9"},{"groupId":"OG001","value":"1095.5","lowerLimit":"1041.5","upperLimit":"1152.2"},{"groupId":"OG002","value":"21.8","lowerLimit":"20.4","upperLimit":"23.4"}]}]},{"title":"MN, Day 209","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"174"},{"groupId":"OG002","value":"153"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"254.4","lowerLimit":"219.4","upperLimit":"294.9"},{"groupId":"OG001","value":"354.8","lowerLimit":"309.2","upperLimit":"407.2"},{"groupId":"OG002","value":"85.3","lowerLimit":"80.6","upperLimit":"90.2"}]}]},{"title":"MN50, Day 1 (Baseline)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"189"},{"groupId":"OG002","value":"186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"46.500","lowerLimit":"45.425","upperLimit":"47.600"},{"groupId":"OG001","value":"46.684","lowerLimit":"44.957","upperLimit":"48.477"},{"groupId":"OG002","value":"47.109","lowerLimit":"45.745","upperLimit":"48.512"}]}]},{"title":"MN50, Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"187"},{"groupId":"OG002","value":"184"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"173.750","lowerLimit":"148.550","upperLimit":"203.225"},{"groupId":"OG001","value":"227.433","lowerLimit":"194.207","upperLimit":"266.343"},{"groupId":"OG002","value":"49.231","lowerLimit":"46.355","upperLimit":"52.285"}]}]},{"title":"MN50, Day 43","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"174"},{"groupId":"OG001","value":"181"},{"groupId":"OG002","value":"180"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1761.660","lowerLimit":"1690.216","upperLimit":"1836.124"},{"groupId":"OG001","value":"1813.480","lowerLimit":"1741.280","upperLimit":"1888.673"},{"groupId":"OG002","value":"48.059","lowerLimit":"45.820","upperLimit":"50.408"}]}]},{"title":"MN50, Day 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"176"},{"groupId":"OG001","value":"177"},{"groupId":"OG002","value":"175"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1632.442","lowerLimit":"1550.245","upperLimit":"1718.998"},{"groupId":"OG001","value":"1656.064","lowerLimit":"1570.464","upperLimit":"1746.330"},{"groupId":"OG002","value":"49.141","lowerLimit":"46.267","upperLimit":"52.194"}]}]},{"title":"MN50, Day 209","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"174"},{"groupId":"OG002","value":"153"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"401.508","lowerLimit":"350.667","upperLimit":"459.720"},{"groupId":"OG001","value":"538.798","lowerLimit":"472.772","upperLimit":"614.045"},{"groupId":"OG002","value":"167.002","lowerLimit":"159.249","upperLimit":"175.133"}]}]}]},{"type":"SECONDARY","title":"Part B: Titer of SARS-CoV-2-Specific nAb","description":"The GM titer (50% inhibitory dose \\[ID50\\], 80% inhibitory dose \\[ID80\\]) of nAb against SARS-CoV-2 pseudotyped viruses as measured by pseudovirus nAb assay is reported. Antibody values reported as below the LLOQ were replaced by 0.5\\*LLOQ. Values that were greater than the ULOQ were converted to the ULOQ if actual values were not available. LLOQ was 18.5 and ULOQ was 45118 for IC50. LLOQ was 14.3 and ULOQ was 10232 for ID80. The 95% CI was calculated based on the t-distribution of the log-transformed values for GM titer, then back transformed to the original scale for presentation. The PP Set included participants with a study injection, required baseline data, had postinjection results at timepoint of primary interest for immunogenicity analysis, no major protocol deviations impacting immune response, and didn't have SARS-CoV-2.","populationDescription":"PP Set. Number Analyzed=participants evaluable at specified timepoint. Immunogenicity samples from the \"Part B: Placebo then 100 ug mRNA\" arm were not tested and no data were generated as results were not thought to provide additional information. After Part B samples were obtained, it was determined that the extensive results for immunogenicity profiles of 2 doses of 100 ug mRNA-1273 that were obtained during Part A of this study and in Study P301 demonstrated enough immune response data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titers","timeFrame":"Days 1 (Baseline), 29, and 181","groups":[{"id":"OG000","title":"Part B: 50 ug mRNA-1273 Then 50 ug mRNA-1273","description":"Participants who chose to be unblinded and received 50 ug mRNA-1273 during Part A, received 1 IM injection of 50 ug mRNA-1273 during Part B."},{"id":"OG001","title":"Part B: 100 ug mRNA-1273 Then 50 ug mRNA-1273","description":"Participants who chose to be unblinded and received 100 ug mRNA-1273 during Part A, received 1 IM injection of 50 ug mRNA-1273 during Part B."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"149"}]}],"classes":[{"title":"ID50, Day 1 (Baseline)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"145"},{"groupId":"OG001","value":"149"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"104.658","lowerLimit":"88.282","upperLimit":"124.070"},{"groupId":"OG001","value":"150.224","lowerLimit":"125.726","upperLimit":"179.495"}]}]},{"title":"ID50, Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"149"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1834.309","lowerLimit":"1600.233","upperLimit":"2102.623"},{"groupId":"OG001","value":"1951.735","lowerLimit":"1729.606","upperLimit":"2202.392"}]}]},{"title":"ID50, Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"147"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"915.331","lowerLimit":"622.504","upperLimit":"1345.904"},{"groupId":"OG001","value":"673.273","lowerLimit":"578.167","upperLimit":"784.025"}]}]},{"title":"ID80, Day 1 (Baseline)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"145"},{"groupId":"OG001","value":"149"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"39.646","lowerLimit":"33.789","upperLimit":"46.518"},{"groupId":"OG001","value":"55.686","lowerLimit":"47.459","upperLimit":"65.341"}]}]},{"title":"ID80, Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"149"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"696.085","lowerLimit":"609.203","upperLimit":"795.358"},{"groupId":"OG001","value":"736.617","lowerLimit":"661.040","upperLimit":"820.835"}]}]},{"title":"ID80, Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"147"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"291.791","lowerLimit":"203.597","upperLimit":"418.189"},{"groupId":"OG001","value":"228.635","lowerLimit":"197.044","upperLimit":"265.291"}]}]}]},{"type":"SECONDARY","title":"Part C: Titer of SARS-CoV-2-Specific nAb","description":"The GM titer (ID50, ID80) of nAb against SARS-CoV-2 pseudotyped viruses (original strain and beta variant \\[B.1.351\\]) as measured by pseudovirus nAb assay is reported. Antibody values reported as below the LLOQ were replaced by 0.5\\*LLOQ. Values that were greater than the ULOQ were converted to the ULOQ if actual values were not available. For NAb ID50 Titers, LLOQ was 18.5 and ULOQ was 45118. For NAb ID80 Titers, LLOQ was 14.3 and ULOQ was 10232. For NAb ID50 Titers against B.1.351, LLOQ was 19.5 and ULOQ was 385.7. For NAb ID80 Titers against B.1.351, LLOQ was 12.5 and ULOQ was 102.2. The 95% CI was calculated based on the t-distribution of the log-transformed values for GM titer, then back transformed to the original scale for presentation.","populationDescription":"PP Set included participants who received any study injection, had required baseline (Day 1) data, had ≥1 post-injection assessment for the analysis endpoint, complied with injection schedule, had post-injection results available for ≥1 assay component corresponding to immunogenicity analysis, did not have SARS-CoV-2 infection, and had no major protocol deviations impacting applicable immune response. Number Analyzed = participants who were evaluable at specified timepoints.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titers","timeFrame":"Days 1 (Baseline), 8, 15, 29, and 181","groups":[{"id":"OG000","title":"Part C: 20 ug mRNA-1273.351","description":"Participants received 1 IM injection of 20 ug mRNA-1273.351 (booster dose) on Day 1."},{"id":"OG001","title":"Part C: 50 ug mRNA-1273.351","description":"Participants received 1 IM injection of 50 ug mRNA-1273.351 (booster dose) on Day 1."},{"id":"OG002","title":"Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture","description":"Participants received 1 IM injection of 50 ug mRNA-1273/mRNA-1273.351 mixture (booster dose) on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"}]}],"classes":[{"title":"ID50 Against Original Strain, Day 1 (Baseline)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"196.107","lowerLimit":"133.338","upperLimit":"288.424"},{"groupId":"OG001","value":"156.011","lowerLimit":"80.546","upperLimit":"302.180"},{"groupId":"OG002","value":"79.572","lowerLimit":"53.625","upperLimit":"118.074"}]}]},{"title":"ID50 Against Original Strain, Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1089.901","lowerLimit":"748.146","upperLimit":"1587.770"},{"groupId":"OG001","value":"1568.894","lowerLimit":"1030.722","upperLimit":"2388.062"},{"groupId":"OG002","value":"1183.096","lowerLimit":"900.313","upperLimit":"1554.700"}]}]},{"title":"ID50 Against Original Strain, Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2221.382","lowerLimit":"1434.353","upperLimit":"3440.255"},{"groupId":"OG001","value":"1725.415","lowerLimit":"1212.131","upperLimit":"2456.053"},{"groupId":"OG002","value":"3082.946","lowerLimit":"1891.502","upperLimit":"5024.874"}]}]},{"title":"ID50 Against Original Strain, Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1808.133","lowerLimit":"1323.211","upperLimit":"2470.767"},{"groupId":"OG001","value":"1757.179","lowerLimit":"1117.782","upperLimit":"2762.324"},{"groupId":"OG002","value":"3691.896","lowerLimit":"2330.908","upperLimit":"5847.548"}]}]},{"title":"ID50 Against Original Strain, Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"512.129","lowerLimit":"303.261","upperLimit":"864.853"}]}]},{"title":"ID80 Against Original Strain, Day 1 (Baseline)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"76.279","lowerLimit":"53.035","upperLimit":"109.712"},{"groupId":"OG001","value":"56.344","lowerLimit":"33.804","upperLimit":"93.911"},{"groupId":"OG002","value":"30.774","lowerLimit":"21.565","upperLimit":"43.915"}]}]},{"title":"ID80 Against Original Strain, Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"448.109","lowerLimit":"300.430","upperLimit":"668.381"},{"groupId":"OG001","value":"500.158","lowerLimit":"341.180","upperLimit":"733.214"},{"groupId":"OG002","value":"458.435","lowerLimit":"351.348","upperLimit":"598.161"}]}]},{"title":"ID80 Against Original Strain, Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"730.018","lowerLimit":"509.454","upperLimit":"1046.073"},{"groupId":"OG001","value":"678.926","lowerLimit":"462.561","upperLimit":"996.498"},{"groupId":"OG002","value":"947.774","lowerLimit":"647.781","upperLimit":"1386.696"}]}]},{"title":"ID80 Against Original Strain, Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"632.263","lowerLimit":"460.549","upperLimit":"868.001"},{"groupId":"OG001","value":"615.967","lowerLimit":"397.103","upperLimit":"955.460"},{"groupId":"OG002","value":"1156.267","lowerLimit":"743.617","upperLimit":"1797.907"}]}]},{"title":"ID80 Against Original Strain, Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"182.837","lowerLimit":"108.300","upperLimit":"308.673"}]}]},{"title":"ID50 Against B.1.351, Day 1 (Baseline)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"45.574","lowerLimit":"28.832","upperLimit":"72.036"},{"groupId":"OG001","value":"32.026","lowerLimit":"19.758","upperLimit":"51.911"},{"groupId":"OG002","value":"18.338","lowerLimit":"13.572","upperLimit":"24.776"}]}]},{"title":"ID50 Against B.1.351, Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"919.281","lowerLimit":"592.738","upperLimit":"1425.720"},{"groupId":"OG001","value":"1088.511","lowerLimit":"670.315","upperLimit":"1767.610"},{"groupId":"OG002","value":"706.141","lowerLimit":"456.010","upperLimit":"1093.475"}]}]},{"title":"ID50 Against B.1.351, Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1088.432","lowerLimit":"736.353","upperLimit":"1608.854"},{"groupId":"OG001","value":"1113.392","lowerLimit":"652.885","upperLimit":"1898.716"},{"groupId":"OG002","value":"1166.830","lowerLimit":"760.230","upperLimit":"1790.895"}]}]},{"title":"ID50 Against B.1.351, Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1537.029","lowerLimit":"1066.352","upperLimit":"2215.458"},{"groupId":"OG001","value":"1116.885","lowerLimit":"714.119","upperLimit":"1746.813"},{"groupId":"OG002","value":"1129.955","lowerLimit":"742.454","upperLimit":"1719.699"}]}]},{"title":"ID50 Against B.1.351, Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"141.773","lowerLimit":"76.471","upperLimit":"262.839"}]}]},{"title":"ID80 Against B.1.351, Day 1 (Baseline)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.403","lowerLimit":"10.870","upperLimit":"27.863"},{"groupId":"OG001","value":"15.046","lowerLimit":"10.088","upperLimit":"22.442"},{"groupId":"OG002","value":"8.326","lowerLimit":"6.727","upperLimit":"10.306"}]}]},{"title":"ID80 Against B.1.351, Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"289.360","lowerLimit":"196.260","upperLimit":"426.626"},{"groupId":"OG001","value":"313.644","lowerLimit":"203.582","upperLimit":"483.210"},{"groupId":"OG002","value":"225.475","lowerLimit":"160.419","upperLimit":"316.915"}]}]},{"title":"ID80 Against B.1.351, Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"435.078","lowerLimit":"300.742","upperLimit":"629.418"},{"groupId":"OG001","value":"371.579","lowerLimit":"228.889","upperLimit":"603.223"},{"groupId":"OG002","value":"413.424","lowerLimit":"284.856","upperLimit":"600.020"}]}]},{"title":"ID80 Against B.1.351, Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"486.398","lowerLimit":"341.630","upperLimit":"692.511"},{"groupId":"OG001","value":"345.827","lowerLimit":"214.472","upperLimit":"557.633"},{"groupId":"OG002","value":"362.540","lowerLimit":"249.138","upperLimit":"527.560"}]}]},{"title":"ID80 Against B.1.351, Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"55.887","lowerLimit":"29.969","upperLimit":"104.220"}]}]}]},{"type":"SECONDARY","title":"Part A: Percentage of Participants With Seroconversion From Baseline","description":"Based on MN titers and MN50 titers of serum nAb against SARS-CoV-2 as measured by live virus MN assays, percentage of participants with seroconversion from baseline are reported with 2-sided 95% CI using the Clopper-Pearson method at each post-baseline timepoint. Seroconversion at a participant level was defined as a change of nAb titer from below the limit of detection (LOD) or LLOQ to equal to or above LOD or LLOQ (respectively), or a 4-times or higher titer ratio in participants with pre-existing nAb titers. Antibody values reported as below the LLOQ were replaced by 0.5\\*LLOQ. Values that were greater than the ULOQ were converted to the ULOQ. For MN, LLOQ was 40 and ULOQ was 1280. For MN50, LLOQ was 91.10 and ULOQ was 2031.87.","populationDescription":"PP Set included randomized participants who received any study injection, had required baseline (Day 1) data, had ≥1 post-injection assessment for the analysis endpoint, complied with injection schedule, had post-injection results available for ≥1 assay component corresponding to immunogenicity analysis, did not have SARS-CoV-2 infection, and had no major protocol deviations impacting applicable immune response. Number Analyzed = participants who were evaluable at specified timepoints.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Days 29, 43, and 57","groups":[{"id":"OG000","title":"Part A: 50 ug mRNA-1273","description":"Participants received 1 IM injection of 50 ug mRNA-1273 on Day 1 and on Day 29."},{"id":"OG001","title":"Part A: 100 ug mRNA-1273","description":"Participants received 1 IM injection of 100 ug mRNA-1273 on Day 1 and on Day 29."},{"id":"OG002","title":"Part A: Placebo","description":"Participants received 1 IM injection of mRNA-1273-matching placebo on Day 1 and on Day 29."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"168"},{"groupId":"OG001","value":"180"},{"groupId":"OG002","value":"178"}]}],"classes":[{"title":"MN Titer, Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"168"},{"groupId":"OG001","value":"180"},{"groupId":"OG002","value":"178"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"78.0","lowerLimit":"70.9","upperLimit":"84.0"},{"groupId":"OG001","value":"88.9","lowerLimit":"83.4","upperLimit":"93.1"},{"groupId":"OG002","value":"1.7","lowerLimit":"0.3","upperLimit":"4.8"}]}]},{"title":"MN Titer, Day 43","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"150"},{"groupId":"OG002","value":"175"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"97.4","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"97.6","upperLimit":"100.0"},{"groupId":"OG002","value":"0.6","lowerLimit":"0.0","upperLimit":"3.1"}]}]},{"title":"MN Titer, Day 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"150"},{"groupId":"OG001","value":"152"},{"groupId":"OG002","value":"171"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"97.6","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"97.6","upperLimit":"100.0"},{"groupId":"OG002","value":"1.8","lowerLimit":"0.4","upperLimit":"5.0"}]}]},{"title":"MN50 Titer, Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"168"},{"groupId":"OG001","value":"180"},{"groupId":"OG002","value":"178"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"65.5","lowerLimit":"57.8","upperLimit":"72.6"},{"groupId":"OG001","value":"76.7","lowerLimit":"69.8","upperLimit":"82.6"},{"groupId":"OG002","value":"1.1","lowerLimit":"0.1","upperLimit":"4.0"}]}]},{"title":"MN50 Titer, Day 43","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"150"},{"groupId":"OG002","value":"175"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"97.4","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"97.6","upperLimit":"100.0"},{"groupId":"OG002","value":"0.6","lowerLimit":"0.0","upperLimit":"3.1"}]}]},{"title":"MN50 Titer, Day 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"150"},{"groupId":"OG001","value":"152"},{"groupId":"OG002","value":"171"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"97.6","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"97.6","upperLimit":"100.0"},{"groupId":"OG002","value":"1.8","lowerLimit":"0.4","upperLimit":"5.0"}]}]}]},{"type":"SECONDARY","title":"Part B: Percentage of Participants With Seroconversion From Baseline","description":"Based on ID50 and ID80 titers of nAb against SARS-CoV-2 pseudotyped viruses as measured by pseudovirus nAb assay, % of participants with seroconversion from baseline reported with 2-sided 95% CI using Clopper-Pearson method at each postbaseline timepoint. Seroconversion at participant level defined as change of nAb titer from below LOD or LLOQ to equal to or above LOD or LLOQ (respectively) or 4-times or higher titer ratio in participants with preexisting nAb titers. Antibody values \\<LLOQ replaced by 0.5\\*LLOQ. Values \\>ULOQ converted to ULOQ. LLOQ: 18.5 and ULOQ: 45118 for IC50. LLOQ: 14.3 and ULOQ: 10232 for ID80. 95% CI calculated based on t-distribution of log-transformed values for GMT, then back transformed to original scale for presentation. PP Set: participants with a study injection, required baseline data, had postinjection results at timepoint of primary interest for immunogenicity analysis, no major protocol deviations impacting immune response, and didn't have SARS-CoV-2.","populationDescription":"PP Set. Number Analyzed=participants evaluable at specified timepoint. Immunogenicity samples from the \"Part B: Placebo then 100 ug mRNA\" arm were not tested and no data were generated as results were not thought to provide additional information. After Part B samples were obtained, it was determined that the extensive results for immunogenicity profiles of 2 doses of 100 ug mRNA-1273 that were obtained during Part A of this study and in Study P301 demonstrated enough immune response data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Days 29 and 181","groups":[{"id":"OG000","title":"Part B: 50 ug mRNA-1273 Then 50 ug mRNA-1273","description":"Participants who chose to be unblinded and received 50 ug mRNA-1273 during Part A, received 1 IM injection of 50 ug mRNA-1273 during Part B."},{"id":"OG001","title":"Part B: 100 ug mRNA-1273 Then 50 ug mRNA-1273","description":"Participants who chose to be unblinded and received 100 ug mRNA-1273 during Part A, received 1 IM injection of 50 ug mRNA-1273 during Part B."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"149"}]}],"classes":[{"title":"ID50, Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"149"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"92.4","lowerLimit":"86.8","upperLimit":"96.2"},{"groupId":"OG001","value":"87.9","lowerLimit":"81.6","upperLimit":"92.7"}]}]},{"title":"ID50, Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"147"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"81.6","lowerLimit":"65.7","upperLimit":"92.3"},{"groupId":"OG001","value":"54.4","lowerLimit":"46.0","upperLimit":"62.6"}]}]},{"title":"ID80, Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"149"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"95.2","lowerLimit":"90.3","upperLimit":"98.0"},{"groupId":"OG001","value":"93.3","lowerLimit":"88.0","upperLimit":"96.7"}]}]},{"title":"ID80, Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"147"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"78.9","lowerLimit":"62.7","upperLimit":"90.4"},{"groupId":"OG001","value":"53.7","lowerLimit":"45.3","upperLimit":"62.0"}]}]}]},{"type":"SECONDARY","title":"Part C: Percentage of Participants With Seroconversion From Baseline","description":"Based on ID50 titers and ID80 titers of nAb against SARS-CoV-2 pseudotyped viruses (original strain and beta variant \\[B.1.351\\]) as measured by pseudovirus nAb assay, percentage of participants with seroconversion from baseline are reported with 2-sided 95% CI using Clopper-Pearson method at each post-baseline timepoint. Seroconversion at participant level defined as a change of nAb titer from below LOD or LLOQ ≥LOD or LLOQ (respectively), or a 4-times or higher titer ratio in participants with pre-existing nAb titers. Antibody values reported as below LLOQ were replaced by 0.5\\*LLOQ. Values \\>ULOQ were converted to ULOQ. NAb ID50 Titers: LLOQ was 18.5 and ULOQ was 45118. NAb ID80 Titers: LLOQ was 14.3 and ULOQ was 10232. NAb ID50 Titers against B.1.351: LLOQ was 19.5 and ULOQ was 385.7. NAb ID80 Titers against B.1.351: LLOQ was 12.5 and ULOQ was 102.2. 95% CI calculated based on t-distribution of log-transformed values for GMT, then back transformed to original scale for presentation.","populationDescription":"PP Set included participants who received any study injection, had required baseline (Day 1) data, had ≥1 post-injection assessment for the analysis endpoint, complied with injection schedule, had post-injection results available for ≥1 assay component corresponding to immunogenicity analysis, did not have SARS-CoV-2 infection, and had no major protocol deviations impacting applicable immune response. Number Analyzed = participants who were evaluable at specified timepoints.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Days 8, 15, 29, and 181","groups":[{"id":"OG000","title":"Part C: 20 ug mRNA-1273.351","description":"Participants received 1 IM injection of 20 ug mRNA-1273.351 (booster dose) on Day 1."},{"id":"OG001","title":"Part C: 50 ug mRNA-1273.351","description":"Participants received 1 IM injection of 50 ug mRNA-1273.351 (booster dose) on Day 1."},{"id":"OG002","title":"Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture","description":"Participants received 1 IM injection of 50 ug mRNA-1273/mRNA-1273.351 mixture (booster dose) on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"}]}],"classes":[{"title":"ID50 Against Original Strain, Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"47.4","lowerLimit":"24.4","upperLimit":"71.1"},{"groupId":"OG001","value":"78.9","lowerLimit":"54.4","upperLimit":"93.9"},{"groupId":"OG002","value":"100","lowerLimit":"83.2","upperLimit":"100.0"}]}]},{"title":"ID50 Against Original Strain, Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"78.9","lowerLimit":"54.4","upperLimit":"93.9"},{"groupId":"OG001","value":"90.0","lowerLimit":"68.3","upperLimit":"98.8"},{"groupId":"OG002","value":"95.0","lowerLimit":"75.1","upperLimit":"99.9"}]}]},{"title":"ID50 Against Original Strain, Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"84.2","lowerLimit":"60.4","upperLimit":"96.6"},{"groupId":"OG001","value":"95.0","lowerLimit":"75.1","upperLimit":"99.9"},{"groupId":"OG002","value":"100","lowerLimit":"83.2","upperLimit":"100.0"}]}]},{"title":"ID50 Against Original Strain, Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"38.9","lowerLimit":"17.3","upperLimit":"64.3"}]}]},{"title":"ID80 Against Original Strain, Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"68.4","lowerLimit":"43.4","upperLimit":"87.4"},{"groupId":"OG001","value":"84.2","lowerLimit":"60.4","upperLimit":"96.6"},{"groupId":"OG002","value":"95.0","lowerLimit":"75.1","upperLimit":"99.9"}]}]},{"title":"ID80 Against Original Strain, Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"84.2","lowerLimit":"60.4","upperLimit":"96.6"},{"groupId":"OG001","value":"95.0","lowerLimit":"75.1","upperLimit":"99.9"},{"groupId":"OG002","value":"100","lowerLimit":"83.2","upperLimit":"100.0"}]}]},{"title":"ID80 Against Original Strain, Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"84.2","lowerLimit":"60.4","upperLimit":"96.6"},{"groupId":"OG001","value":"95.0","lowerLimit":"75.1","upperLimit":"99.9"},{"groupId":"OG002","value":"95.0","lowerLimit":"75.1","upperLimit":"99.9"}]}]},{"title":"ID80 Against Original Strain, Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"38.9","lowerLimit":"17.3","upperLimit":"64.3"}]}]},{"title":"ID50 Against B.1.351, Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"82.4","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"82.4","upperLimit":"100.0"},{"groupId":"OG002","value":"100","lowerLimit":"83.2","upperLimit":"100.0"}]}]},{"title":"ID50 Against B.1.351, Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"94.7","lowerLimit":"74.0","upperLimit":"99.9"},{"groupId":"OG001","value":"100","lowerLimit":"83.2","upperLimit":"100.0"},{"groupId":"OG002","value":"100","lowerLimit":"83.2","upperLimit":"100.0"}]}]},{"title":"ID50 Against B.1.351, Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"82.4","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"83.2","upperLimit":"100.0"},{"groupId":"OG002","value":"100","lowerLimit":"83.2","upperLimit":"100.0"}]}]},{"title":"ID50 Against B.1.351, Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"61.1","lowerLimit":"35.7","upperLimit":"82.7"}]}]},{"title":"ID80 Against B.1.351, Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"94.7","lowerLimit":"74.0","upperLimit":"99.9"},{"groupId":"OG001","value":"94.7","lowerLimit":"74.0","upperLimit":"99.9"},{"groupId":"OG002","value":"100","lowerLimit":"83.2","upperLimit":"100.0"}]}]},{"title":"ID80 Against B.1.351, Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"94.7","lowerLimit":"74.0","upperLimit":"99.9"},{"groupId":"OG001","value":"100","lowerLimit":"83.2","upperLimit":"100.0"},{"groupId":"OG002","value":"100","lowerLimit":"83.2","upperLimit":"100.0"}]}]},{"title":"ID80 Against B.1.351, Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"82.4","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"83.2","upperLimit":"100.0"},{"groupId":"OG002","value":"100","lowerLimit":"83.2","upperLimit":"100.0"}]}]},{"title":"ID80 Against B.1.351, Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"55.6","lowerLimit":"30.8","upperLimit":"78.5"}]}]}]},{"type":"PRIMARY","title":"Part C: Level of SARS-CoV-2-Specific bAb as Measured by MSD","description":"The GM level of SARS-CoV-2 protein antibody against B.1.351, as measured by MSD MULTIPLEX is reported. Antibody values reported as below the LLOQ were replaced by 0.5\\*LLOQ. Values that were greater than the ULOQ are converted to the ULOQ. LLOQ was 18 and ULOQ was 4200000. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GM value, respectively, then back transformed to the original scale for presentation.","populationDescription":"PP Set included participants who received any study injection, had required baseline (Day 1) data, had ≥1 post-injection assessment for the analysis endpoint, complied with injection schedule, had post-injection results available for ≥1 assay component corresponding to immunogenicity analysis, did not have SARS-CoV-2 infection, and had no major protocol deviations impacting applicable immune response. Number Analyzed = participants who were evaluable at specified timepoints.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"AU/mL","timeFrame":"Days 1 (Baseline), 8, 15, and 29","groups":[{"id":"OG000","title":"Part C: 20 ug mRNA-1273.351","description":"Participants received 1 IM injection of 20 ug mRNA-1273.351 (booster dose) on Day 1."},{"id":"OG001","title":"50 ug mRNA-1273.351","description":"Participants received 1 IM injection of 50 ug mRNA-1273.351 (booster dose) on Day 1."},{"id":"OG002","title":"Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture","description":"Participants received 1 IM injection of 50 ug mRNA-1273/mRNA-1273.351 mixture (booster dose) on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"}]}],"classes":[{"title":"Day 1 (Baseline)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"59742.3","lowerLimit":"43057.8","upperLimit":"82891.8"},{"groupId":"OG001","value":"44921.5","lowerLimit":"28539.6","upperLimit":"70706.5"},{"groupId":"OG002","value":"33409.8","lowerLimit":"25264.8","upperLimit":"44180.6"}]}]},{"title":"Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"240180.0","lowerLimit":"166361.1","upperLimit":"346754.3"},{"groupId":"OG001","value":"267002.2","lowerLimit":"199939.9","upperLimit":"356558.2"},{"groupId":"OG002","value":"228572.0","lowerLimit":"178986.7","upperLimit":"291894.2"}]}]},{"title":"Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"297880.2","lowerLimit":"224089.6","upperLimit":"395969.4"},{"groupId":"OG001","value":"418215.3","lowerLimit":"311988.7","upperLimit":"560610.2"},{"groupId":"OG002","value":"384521.1","lowerLimit":"282461.4","upperLimit":"523457.3"}]}]},{"title":"Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"297962.7","lowerLimit":"227337.5","upperLimit":"390528.5"},{"groupId":"OG001","value":"345765.9","lowerLimit":"251640.5","upperLimit":"475098.5"},{"groupId":"OG002","value":"367714.1","lowerLimit":"268913.2","upperLimit":"502815.1"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Up to Month 15","description":"Safety Set: All participants who received any study injection in their respective part of the study. Note, not all solicited ARs were considered AEs. The Investigator reviewed whether the solicited AR was also to be recorded as an AE.","eventGroups":[{"id":"EG000","title":"Part A: 50 ug mRNA-1273","description":"Participants received 1 IM injection of 50 ug mRNA-1273 on Day 1 and on Day 29.","deathsNumAffected":0,"deathsNumAtRisk":200,"seriousNumAffected":5,"seriousNumAtRisk":200,"otherNumAffected":105,"otherNumAtRisk":200},{"id":"EG001","title":"Part A: 100 ug mRNA-1273","description":"Participants received 1 IM injection of 100 ug mRNA-1273 on Day 1 and on Day 29.","deathsNumAffected":0,"deathsNumAtRisk":200,"seriousNumAffected":2,"seriousNumAtRisk":200,"otherNumAffected":76,"otherNumAtRisk":200},{"id":"EG002","title":"Part A: Placebo","description":"Participants received 1 IM injection of mRNA-1273-matching placebo on Day 1 and on Day 29.","deathsNumAffected":0,"deathsNumAtRisk":200,"seriousNumAffected":0,"seriousNumAtRisk":200,"otherNumAffected":94,"otherNumAtRisk":200},{"id":"EG003","title":"Part B: 50 ug mRNA-1273 Then 50 ug mRNA-1273","description":"Participants who chose to be unblinded and received 50 ug mRNA-1273 during Part A, received 1 IM injection of 50 ug mRNA-1273 during Part B.","deathsNumAffected":0,"deathsNumAtRisk":173,"seriousNumAffected":2,"seriousNumAtRisk":173,"otherNumAffected":51,"otherNumAtRisk":173},{"id":"EG004","title":"Part B: 100 ug mRNA-1273 Then 50 ug mRNA-1273","description":"Participants who chose to be unblinded and received 100 ug mRNA-1273 during Part A, received 1 IM injection of 50 ug mRNA-1273 during Part B.","deathsNumAffected":0,"deathsNumAtRisk":171,"seriousNumAffected":2,"seriousNumAtRisk":171,"otherNumAffected":62,"otherNumAtRisk":171},{"id":"EG005","title":"Part B: Placebo Then 100 ug mRNA-1273","description":"Participants who chose to be unblinded and received mRNA-1273-matching placebo during Part A, received 2 IM injections of 100 ug mRNA-1273 28 days apart during Part B.","deathsNumAffected":0,"deathsNumAtRisk":158,"seriousNumAffected":2,"seriousNumAtRisk":158,"otherNumAffected":70,"otherNumAtRisk":158},{"id":"EG006","title":"Part C: 20 ug mRNA-1273.351","description":"Participants received 1 IM injection of 20 ug mRNA-1273.351 (booster dose) on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":20,"seriousNumAffected":0,"seriousNumAtRisk":20,"otherNumAffected":8,"otherNumAtRisk":20},{"id":"EG007","title":"Part C: 50 ug mRNA-1273.351","description":"Participants received 1 IM injection of 50 ug mRNA-1273.351 (booster dose) on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":20,"seriousNumAffected":1,"seriousNumAtRisk":20,"otherNumAffected":4,"otherNumAtRisk":20},{"id":"EG008","title":"Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture","description":"Participants received 1 IM injection of 50 ug mRNA-1273/mRNA-1273.351 mixture (booster dose) on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":20,"seriousNumAffected":0,"seriousNumAtRisk":20,"otherNumAffected":9,"otherNumAtRisk":20}],"seriousEvents":[{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Nervous system cyst","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Spondylolisthesis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Abortion missed","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Abortion spontaneous","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Struck by lightning","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Pericarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Tendon rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Atrioventricular block complete","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Peptic ulcer perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Pancreatic carcinoma stage IV","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":1,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]}],"otherEvents":[{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":200},{"groupId":"EG001","numAffected":2,"numAtRisk":200},{"groupId":"EG002","numAffected":4,"numAtRisk":200},{"groupId":"EG003","numAffected":2,"numAtRisk":173},{"groupId":"EG004","numAffected":2,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":200},{"groupId":"EG001","numAffected":2,"numAtRisk":200},{"groupId":"EG002","numAffected":26,"numAtRisk":200},{"groupId":"EG003","numAffected":9,"numAtRisk":173},{"groupId":"EG004","numAffected":8,"numAtRisk":171},{"groupId":"EG005","numAffected":16,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":200},{"groupId":"EG001","numAffected":2,"numAtRisk":200},{"groupId":"EG002","numAffected":3,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":2,"numAtRisk":171},{"groupId":"EG005","numAffected":2,"numAtRisk":158},{"groupId":"EG006","numAffected":1,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":3,"numAtRisk":200},{"groupId":"EG003","numAffected":4,"numAtRisk":173},{"groupId":"EG004","numAffected":4,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":3,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Viral upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":2,"numAtRisk":173},{"groupId":"EG004","numAffected":2,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Acute sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":2,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":4,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Otitis media","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":2,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Suspected COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":2,"numAtRisk":200},{"groupId":"EG003","numAffected":2,"numAtRisk":173},{"groupId":"EG004","numAffected":2,"numAtRisk":171},{"groupId":"EG005","numAffected":3,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Eye infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Fungal skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":2,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":1,"numAtRisk":20}]},{"term":"Infected bite","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Tinea pedis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Tooth abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":3,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Tooth infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Urethritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Asymptomatic COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":3,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":1,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Gingivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Herpes simplex","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Hordeolum","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Localised infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Otitis externa","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Basal cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Benign neoplasm of skin","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Lymphadenopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":2,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":1,"numAtRisk":20}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Seasonal allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":2,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Allergy to arthropod sting","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Hyperoestrogenism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Gout","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Hyperlipidaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Insulin resistance","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Vitamin B12 deficiency","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Vitamin D deficiency","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Hypercholesterolaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":200},{"groupId":"EG001","numAffected":2,"numAtRisk":200},{"groupId":"EG002","numAffected":3,"numAtRisk":200},{"groupId":"EG003","numAffected":2,"numAtRisk":173},{"groupId":"EG004","numAffected":2,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":1,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":200},{"groupId":"EG001","numAffected":4,"numAtRisk":200},{"groupId":"EG002","numAffected":2,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":2,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":1,"numAtRisk":20}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":2,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Major depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":200},{"groupId":"EG001","numAffected":9,"numAtRisk":200},{"groupId":"EG002","numAffected":8,"numAtRisk":200},{"groupId":"EG003","numAffected":3,"numAtRisk":173},{"groupId":"EG004","numAffected":8,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":1,"numAtRisk":20}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Migraine","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":2,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Tension headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Ageusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Lethargy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":2,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Sinus headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Neuralgia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Restless legs syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Conjunctivitis allergic","organSystem":"Eye disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Glaucoma","organSystem":"Eye disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Deafness unilateral","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Ear pain","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Excessive cerumen production","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Diastolic dysfunction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":2,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":2,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":2,"numAtRisk":20},{"groupId":"EG008","numAffected":2,"numAtRisk":20}]},{"term":"Diastolic hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":4,"numAtRisk":200},{"groupId":"EG003","numAffected":2,"numAtRisk":173},{"groupId":"EG004","numAffected":3,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":200},{"groupId":"EG001","numAffected":3,"numAtRisk":200},{"groupId":"EG002","numAffected":2,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":3,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":2,"numAtRisk":171},{"groupId":"EG005","numAffected":4,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":3,"numAtRisk":171},{"groupId":"EG005","numAffected":3,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Rhinitis allergic","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Nasal pruritus","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Pharyngeal erythema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Sneezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Dry throat","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Sinus congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":2,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Upper respiratory tract inflammation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":200},{"groupId":"EG001","numAffected":4,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":2,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":2,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":2,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Aphthous ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Dental caries","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Diverticulum","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Inguinal hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Irritable bowel syndrome","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Oesophageal food impaction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Paraesthesia oral","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Tongue discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Abdominal tenderness","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Duodenitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Large intestine polyp","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Odynophagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Oral disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Dermatitis contact","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":200},{"groupId":"EG001","numAffected":3,"numAtRisk":200},{"groupId":"EG002","numAffected":3,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":2,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Acne","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":2,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Ecchymosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Skin discolouration","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Angioedema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Hirsutism","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Rash papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":200},{"groupId":"EG001","numAffected":4,"numAtRisk":200},{"groupId":"EG002","numAffected":4,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":2,"numAtRisk":171},{"groupId":"EG005","numAffected":2,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":1,"numAtRisk":20},{"groupId":"EG008","numAffected":2,"numAtRisk":20}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":200},{"groupId":"EG001","numAffected":2,"numAtRisk":200},{"groupId":"EG002","numAffected":3,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":4,"numAtRisk":171},{"groupId":"EG005","numAffected":2,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":1,"numAtRisk":20},{"groupId":"EG008","numAffected":3,"numAtRisk":20}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":200},{"groupId":"EG001","numAffected":2,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":2,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":2,"numAtRisk":171},{"groupId":"EG005","numAffected":2,"numAtRisk":158},{"groupId":"EG006","numAffected":1,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":2,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Plantar fasciitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Axillary mass","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Joint swelling","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Musculoskeletal stiffness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Periarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Rotator cuff syndrome","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Tendonitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Bursitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":2,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":1,"numAtRisk":20}]},{"term":"Exostosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Hypertonic bladder","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Breast pain","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Prostatomegaly","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Postmenopausal haemorrhage","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Testicular cyst","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":200},{"groupId":"EG001","numAffected":5,"numAtRisk":200},{"groupId":"EG002","numAffected":7,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":7,"numAtRisk":171},{"groupId":"EG005","numAffected":5,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":1,"numAtRisk":20},{"groupId":"EG008","numAffected":1,"numAtRisk":20}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":200},{"groupId":"EG001","numAffected":3,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Injection site induration","organSystem":"General disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":4,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":3,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":2,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Injection site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":4,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":2,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Axillary pain","organSystem":"General disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":2,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":2,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":3,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Injection site bruising","organSystem":"General disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":2,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Injection site mass","organSystem":"General disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Injection site pruritus","organSystem":"General disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Mass","organSystem":"General disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Peripheral swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":1,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Blood pressure increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":2,"numAtRisk":200},{"groupId":"EG002","numAffected":2,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":1,"numAtRisk":20}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Blood cholesterol increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Blood pressure diastolic increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Haematocrit increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Haemoglobin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Hormone level abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Platelet count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Staphylococcus test positive","organSystem":"Investigations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Blood testosterone decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Blood triglycerides increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Cardiac murmur","organSystem":"Investigations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Computerised tomogram coronary artery abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Heart rate decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":2,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Vitamin D decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Arthropod bite","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Meniscus injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":2,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Muscle strain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":2,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Concussion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Breast injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Chemical burn","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Corneal abrasion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Epicondylitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Foreign body in eye","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Heat exhaustion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Joint injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Limb injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Muscle contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Muscle rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Post-traumatic pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Procedural pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Road traffic accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Tendon rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":2,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Tooth fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Nail avulsion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Skin laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":2,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Tendon injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":1,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Ear infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Respiratory tract infection viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Sinusitis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":2,"numAtRisk":158},{"groupId":"EG006","numAffected":1,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":1,"numAtRisk":20}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":2,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Cryptosporidiosis infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Gastrointestinal bacterial overgrowth","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Laryngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Onychomycosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Skin papilloma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Lymphadenitis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Thyroid cyst","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Dyslipidaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Obesity","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Attention deficit hyperactivity disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Burning sensation","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Memory impairment","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Facial paralysis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Retinal detachment","organSystem":"Eye disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":1,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Macular fibrosis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":2,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Ventricular extrasystoles","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Pharyngeal inflammation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Respiratory disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Sleep apnoea syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Wheezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Respiratory tract congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":2,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Upper respiratory tract congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Pulpless tooth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Dermatitis exfoliative","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Rash pruritic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":2,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":3,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Haematoma muscle","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Intervertebral disc degeneration","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Osteopenia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Sjogren's syndrome","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Spinal osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Pregnancy","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Benign prostatic hyperplasia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Ovarian cyst","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Injection site rash","organSystem":"General disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Heart rate increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Glycosylated haemoglobin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Animal bite","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":2,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":1,"numAtRisk":20}]},{"term":"Foot fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Hand fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":1,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Fascial rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Wrist fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":1,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Humerus fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":1,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Cystitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":1,"numAtRisk":20}]},{"term":"Labyrinthitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":1,"numAtRisk":20}]},{"term":"Pyelonephritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":1,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Staphylococcal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":1,"numAtRisk":20}]},{"term":"Pharyngitis streptococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":2,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Thyroid disorder","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":1,"numAtRisk":20}]},{"term":"Arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":1,"numAtRisk":20}]},{"term":"Extrasystoles","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":1,"numAtRisk":20}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":1,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Nasal polyps","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":1,"numAtRisk":20}]},{"term":"Nasal septum deviation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":1,"numAtRisk":20}]},{"term":"Hepatic lesion","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":1,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]},{"term":"Intervertebral disc protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":0,"numAtRisk":20},{"groupId":"EG008","numAffected":2,"numAtRisk":20}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":200},{"groupId":"EG002","numAffected":0,"numAtRisk":200},{"groupId":"EG003","numAffected":0,"numAtRisk":173},{"groupId":"EG004","numAffected":0,"numAtRisk":171},{"groupId":"EG005","numAffected":0,"numAtRisk":158},{"groupId":"EG006","numAffected":0,"numAtRisk":20},{"groupId":"EG007","numAffected":1,"numAtRisk":20},{"groupId":"EG008","numAffected":0,"numAtRisk":20}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":true},"pointOfContact":{"title":"Moderna Clinical Trials Support Center","organization":"ModernaTX, Inc.","email":"clinicaltrials@modernatx.com","phone":"1-877-777-7187"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2021-04-28","uploadDate":"2022-10-21T13:41","filename":"Prot_000.pdf","size":2004678},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2021-11-17","uploadDate":"2022-10-21T13:41","filename":"SAP_001.pdf","size":1560970},{"typeAbbrev":"ICF","hasProtocol":false,"hasSap":false,"hasIcf":true,"label":"Informed Consent Form","date":"2021-08-09","uploadDate":"2022-10-21T13:41","filename":"ICF_002.pdf","size":429062}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2022-11-16","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D018352","term":"Coronavirus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D000086382","term":"COVID-19"}],"ancestors":[{"id":"D003333","term":"Coronaviridae Infections"},{"id":"D030341","term":"Nidovirales Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D007239","term":"Infections"},{"id":"D011024","term":"Pneumonia, Viral"},{"id":"D011014","term":"Pneumonia"},{"id":"D012141","term":"Respiratory Tract Infections"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]}},"hasResults":true}